The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Pregabalin: A New Neuromodulator with Broad Therapeutic Indications
Abstract
OBJECTIVE: To review pregabalin's pharmacology, pharmacokinetics, efficacy, and adverse effects in the treatment of neuropathic pain, epilepsy, and anxiety. DATA SOURCES: A MEDLINE search (1993–October 2005) for peer-reviewed English-language publications was performed. Abstracts from professional meetings were also included. Key terms were anxiety, diabetic neuropathy, epilepsy, neuropathic pain, postherpetic neuralgia, pregabalin, and seizures. STUDY SELECTION AND DATA EXTRACTION: Basic pharmacology data were extracted from animal studies; pharmacokinetic data were extracted from human studies. Multicenter, double-blind, placebo-controlled, parallel-group studies were included to describe the efficacy and adverse effects of pregabalin. DATA SYNTHESIS: Pregabalin is a new agent that exerts its pharmacodynamic effect by modulating voltage-gated calcium channels. Pregabalin has a linear pharmacokinetic profile. It is completely absorbed, not bound to plasma proteins, not metabolized, and eliminated unchanged through the kidneys. Doses must be adjusted in patients with renal insufficiency. Clinical trials showed that pregabalin is effective in neuropathic pain associated with postherpetic neuralgia, diabetic peripheral neuropathy, in partial epilepsy as adjunctive therapy, and in generalized and social anxiety disorders. The most common adverse effects were dizziness and somnolence. Few serious adverse effects were reported. Pregabalin should not be discontinued rapidly. CONCLUSIONS: Pregabalin is an effective and safe analgesic, antiepileptic, and anxiolytic medicine. It will provide a new treatment option for patients with neuropathic pain and partial epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Pande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227
Pharmacotherapy of social phobia
Davidson, J. R. T. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s417.7.x · Cited by 69
Cited by
Pharmacological Management of Persistent Pain in Older Persons
(2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00699.x · Cited by 916
Neuropathic pain: a practical guide for the clinician
Gilron, I. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.060146 · Cited by 450
Efficacy of pregabalin in acute postoperative pain: a meta-analysis
Zhang, J., Ho, K.-Y., & Wang, Y. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer027 · Cited by 357
Pregabalin: Its Pharmacology and Use in Pain Management
Gajraj, N. M. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000287643.13410.5e · Cited by 343
Tassone, D. M., Boyce, E., Guyer, J., & Nuzum, D. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.013 · Cited by 275
Metadata
- Authors
- Shneker, B. F., & McAuley, J. W.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2005-12
- Volume
- 39
- Issue
- 12
- Pages
- 2029-2037
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2155118474
- Cited by
- 178
- References
- 4
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pregabalin: A New Neuromodulator with Broad Therapeutic Indications. https://app.cochat.ai/papers/10.1345/aph.1g078
- The paper
- Shneker, B. F., & McAuley, J. W. (2005). Pregabalin: A New Neuromodulator with Broad Therapeutic Indications. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1g078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.